Media and Press

iMedicor Launches Phase I Product Marketing Program for MuGard

Program's Initial Phase Includes On-going Product Sampling to Centers of Excellence and Key Opinion Leaders 

NANUET, NY--(07/27/10) - iMedicor (OTC.BB:VMCI) today announced its launch of Access Pharmaceuticals' MuGard product through its pharma online marketing portal, ClearLobby, and its direct sales channel, Direct Medical Solutions (DMS). The initial phase of the marketing program includes a targeted MuGard sampling program to select iMedicor users and the DMS' physician network. As previously announced, iMedicor has been selected by Access Pharmaceuticals, Inc. (ACCP) to support the North American commercial launch efforts of its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, a debilitating side effect of radiotherapy and/or chemotherapy.

MuGard is now being introduced to Centers of Excellence, Key Opinion Leaders, cancer research centers and selected physicians in the United States. The initial release of MuGard samples is part of a joint project that includes participation from iMedicor's user base and DMS, a network of direct field representatives with strong relationships to physicians and their practices. The full national launch is expected during the third quarter using iMedicor's highly targeted Physician Communication System (PCS), and iMedicor's strategic partnership with Direct Medical Solutions (DMS) and other strategic partners.

"After many months of planning, we look forward to assisting Access Pharma with its introduction of MuGard on a national level," said Fred Zolla, CEO of iMedicor. He continued, "MuGard represents a potential blockbuster product that could significantly improve the quality of life for patients undergoing certain cancer treatments. iMedicor's ability to deliver essential information from a trusted source to specific physician audiences will significantly increase Access Pharma's marketing ROI."

"Our collective efforts have led to the positive acceptance of the first phase sampling program throughout the DMS network," commented Marian Bartosiewicz, CEO of DMS. She continued, "We are pleased to be part of the introduction of a product like MuGard that can offer measurable relief to patients undergoing radiation and chemotherapy."

"Teaming up with iMedicor and DMS is an important strategic step in launching MuGard in North America as it provides us the ability to introduce MuGard more rapidly and cost-effectively than we would expect through traditional distribution channels to doctors," said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc. He continued, "Along with this initial and on-going sample program, Access will be able to utilize the medical education aspects of the iMedicor system to further inform doctors about oral mucositis and MuGard, and to accelerate commercial uptake in the U.S. market."

The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide. iMedicor and DMS will share in a portion of the revenue as sales are developed within North America. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops.

About IMedicor:

iMedicor is the only HIPAA-compliant solution for interoperable health information exchange (HIE) that offers services at no cost to healthcare providers and patients. The iMedicor portal enables physicians, administrators and other qualified healthcare professionals to exchange medical records, files and images in a HIPAA compliant environment and allows disparate EMR (electronic medical record) systems to integrate and share data. iMedicor also delivers important information on new drugs and treatments to its members as well as the members of its syndicated partners through their ClearLobby platform. More information on iMedicor is available at www.imedicor.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com

About Direct Medical Solutions:

DMS provides a one-stop shopping network of "Best of Breed" ancillary, medical and operational strategies to compliment healthcare businesses. The DMS network of products offers innovative ways to improve the bottom line of a healthcare practice. DMS' approach is that of an advisor, analyzing key practice attributes and workflow to customize a plan for services to compliment and integrate into core business operations. By implementing a "One Stop Shopping" business model and integrating technology designed to move healthcare in the direction of "Meaningful Use", practices can meet the demands of the new regulations, increase revenue, while enhancing patient satisfaction. As consumer demands continue to intensify; healthcare professionals who want to maintain a competitive edge in the industry, must look to come up with innovative concepts that will enhance their business, offer consumer convenience and additional benefits to retain patient loyalty.

The statements contained herein, other than historical information, are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance of iMedicor’s products and services; the nonexclusive and terminable-at-will nature of certain of the company's partnerships and agreements; rapid technological change affecting demand for our products and services; competition from companies providing similar products and services, availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filing s with the Securities and Exchange Commission.